Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
作者信息
Arnold Suzanne V, Gosch Kensey L, Dolan Chantal, Fine Jennifer T, Masri Ahmad, Saberi Sara, Wang Andrew, Elliott Perry M, Hegde Sheila M, Lam Jenny, Sehnert Amy J, Cresci Sharon, Bach Richard G, Spertus John A
机构信息
University of Missouri-Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute (S.V.A., K.L.G., J.A.S.).
CMD Consulting, Sandy, UT (C.D.).
出版信息
Circulation. 2024 Nov 5;150(19):1560-1562. doi: 10.1161/CIRCULATIONAHA.123.067470. Epub 2024 Nov 4.
Abstract
摘要
相似文献
1
Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.梗阻性肥厚型心肌病患者超声心动图参数与健康状况的关联：来自EXPLORER-HCM研究的见解
Circulation. 2024 Nov 5;150(19):1560-1562. doi: 10.1161/CIRCULATIONAHA.123.067470. Epub 2024 Nov 4.
2
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.肥厚型梗阻性心肌病女性患者与男性患者接受 Mavacamten 治疗的效果对比：EXPLORER-HCM 研究的新发现
Circulation. 2024 Feb 13;149(7):498-509. doi: 10.1161/CIRCULATIONAHA.123.065600. Epub 2023 Nov 14.
3
Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.预测美伐他汀治疗美国梗阻性肥厚型心肌病的长期临床价值：净健康效益评估。
Clin Ther. 2022 Jan;44(1):52-66.e2. doi: 10.1016/j.clinthera.2021.11.006. Epub 2021 Dec 12.
4
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.马卡丹特治疗伴或不伴高血压的梗阻性肥厚型心肌病：EXPLORER-HCM 试验的事后分析。
JACC Heart Fail. 2024 Mar;12(3):567-579. doi: 10.1016/j.jchf.2023.07.030. Epub 2023 Oct 18.
5
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.梗阻性肥厚型心肌病患者行室间隔减容术治疗：肌球蛋白抑制与左心室舒张功能——来自 VALOR-HCM 研究的结果。
Circ Cardiovasc Imaging. 2022 Dec;15(12):e014986. doi: 10.1161/CIRCIMAGING.122.014986. Epub 2022 Nov 6.
6
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
7
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.评估有症状梗阻性肥厚型心肌病患者的健康相关生命质量：EXPLORER-HCM 试验中基于 EQ-5D 的效用。
J Med Econ. 2022 Jan-Dec;25(1):51-58. doi: 10.1080/13696998.2021.2011301.
8
Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy.性别对非梗阻性肥厚型心肌病中心力衰竭表现的影响。
Heart Vessels. 2020 Feb;35(2):214-222. doi: 10.1007/s00380-019-01492-0. Epub 2019 Sep 3.
9
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.在当代肥厚型梗阻性心肌病患者人群中，真实世界对马卡坦特的应用。
Eur J Heart Fail. 2024 Jan;26(1):59-64. doi: 10.1002/ejhf.3120. Epub 2024 Jan 2.
10
A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy.EXPLORER-HCM 研究的通俗易懂总结：mavacamten 治疗梗阻性肥厚型心肌病。
Future Cardiol. 2021 Oct;17(7):1269-1275. doi: 10.2217/fca-2021-0044. Epub 2021 May 21.
引用本文的文献
1
Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study.麦卡姆坦对中国梗阻性肥厚型心肌病患者超声心动图特征的影响：EXPLORER-CN研究结果
Cardiol Ther. 2025 Jun;14(2):267-282. doi: 10.1007/s40119-025-00409-5. Epub 2025 Apr 29.
本文引用的文献
1
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy.堪萨斯城心肌病问卷在有症状梗阻性肥厚型心肌病中的验证。
JACC Heart Fail. 2022 Aug;10(8):531-539. doi: 10.1016/j.jchf.2022.03.002. Epub 2022 May 4.
2
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.马卡丹特对梗阻性肥厚型心肌病有症状患者超声心动图特征的影响。
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
3
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
5
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.堪萨斯城心肌病问卷的开发与评估：一种用于心力衰竭的新健康状况测量方法。
J Am Coll Cardiol. 2000 Apr;35(5):1245-55. doi: 10.1016/s0735-1097(00)00531-3.
Zotero 插件